| Autor: |
Archer PA; Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, IBB 2310, 315 Ferst Drive NW, Atlanta, GA 30332, USA. susan.thomas@gatech.edu.; School of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA., Heiler AJ; Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, IBB 2310, 315 Ferst Drive NW, Atlanta, GA 30332, USA. susan.thomas@gatech.edu.; School of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA., Bourque AR; Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, IBB 2310, 315 Ferst Drive NW, Atlanta, GA 30332, USA. susan.thomas@gatech.edu.; George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA., Alapan Y; George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA., Thomas SN; Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, IBB 2310, 315 Ferst Drive NW, Atlanta, GA 30332, USA. susan.thomas@gatech.edu.; George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA.; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA.; Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA. |
| Abstrakt: |
Lymph nodes (LNs) house a large proportion of the body's leukocytes. Accordingly, engineered nanomaterials are increasingly developed to direct therapeutics to LNs to enhance their efficacy. Yet while lymphatic delivery of nanomaterials to LNs upon locoregional injection has been extensively evaluated, nanomaterial delivery to LN-localized leukocytes after intravenous administration has not been systematically explored nor benchmarked. In this work, a panel of inert, fluorescent nanoscale tracers and drug delivery vehicles were utilized to interrogate intravenous versus locoregionally administered nanomaterial access to LNs and leukocyte subsets therein. Hydrodynamic size and material effects on LN accumulation extents were similar between intravenous versus intradermal injection routes. Nanomaterial distribution to various LN leukocyte subsets differed substantially with injection route, however, in a manner not proportional to total LN accumulation. While intravenously administered nanomaterials accumulated in LNs lowly compared to systemic tissues, in sharp contrast to locoregional delivery, they exhibited size-dependent but material-independent access to immune cells within the LN parenchyma, which are not easily accessed with locoregional delivery. |
